Nuked 
Hello, tech enthusiasts! Today’s story brings exciting news from the thriving innovation hub of Cambridge, UK. A fresh breeze of opportunity is blowing through our tech landscape.
Cambridge Innovation Capital (CIC), known for its unique focus on the Cambridge ecosystem, has launched a groundbreaking £100 million ($126 million) Opportunity Fund aimed specifically at deep tech and life sciences companies. This initiative addresses a long-standing gap in funding for later-stage startups in the UK.
Why is this important, you may ask? Well, the UK historically lacks the vast levels of growth funding that US startups enjoy. To illustrate, there are reportedly seven times more large-size VC funds in the US compared to Europe. Therefore, the emergence of this new fund is a significant development.
The Opportunity Fund, anchored by Aviva Investors and British Patient Capital, will allow for investments up to £20 million ($25.2 million) in promising companies that are transitioning into the later stages of their growth journey.
Among their early investments are notable players like Pragmatic Semiconductor, which has raised an impressive $389.3 million to date, and Riverlane, a quantum computing startup securing $120.7 million.
As the UK’s deep tech scene continues to mature, it’s crucial to keep thriving talent and innovation at home. This fund aims to do just that, preventing talented startups from migrating to other regions with more substantial financial backing, particularly the US.
The UK government is also on board with measures to foster innovation through their “AI Action Plan,” which seeks to bolster the existing tech ecosystems in areas like Oxford and Cambridge while promoting sustainable growth.
Andrew Williamson, the Managing Partner at CIC, explained that previously, their investments were mainly in early-stage companies. However, as companies grow and require more capital, the need for a dedicated fund like this became apparent.
With significant previous exits from CIC’s portfolio, including notable successes like Gyroscope Therapeutics and PetMedix, the Opportunity Fund stands to boost the chances of success for many innovative ventures on this side of the pond.
In summary, this move represents an exciting shift for the UK tech sector, ensuring our vibrant startup landscape is well-equipped to compete on a global scale. Here’s to a future filled with innovation!
